Page 42 - Read Online

Page 14 of 22 Strassheim et al. Vessel Plus 2018;2:29 I http://dx.doi.org/10.20517/2574-1209.2018.44

35. Nakagawa Y, Kishida K, Kihara S, Funahashi T, Shimomura I. Adiponectin ameliorates hypoxia-induced pulmonary arterial remodeling.
Biochem Biophys Res Commun 2009;382:183-8.
36. Isobe S, Kataoka M, Kawakami T, Fukuda K. Adiponectin in chronic thromboembolic pulmonary hypertension. Circ J 2018;82:1466-8.
37. Telli G, Tel BC, Yersal N, Korkusuz P, Gumusel B. Effect of intermedin/adrenomedullin2 on the pulmonary vascular bed in hypoxia-
induced pulmonary hypertensive rats. Life Sci 2018;192:62-7.
38. Chawla S, Rahar B, Saxena S. S1P prophylaxis mitigates acute hypobaric hypoxia-induced molecular, biochemical, and metabolic
disturbances: a preclinical report. IUBMB Life 2016;68:365-75.
39. Harada-Shiba M, Takamisawa I, Miyata K, Ishii T, Nishiyama N, Itaka K, Kangawa K, Yoshihara F, Asada Y, Hatakeyama K, Nagaya
N, Kataoka K. Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates monocrotaline-induced pulmonary
hypertension in rats. Mol Ther 2009;17:1180-6.
40. Burnouf C, Pruniaux MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des
2002;8:1255-96.
41. Tobin JV, Zimmer DP, Shea C, Germano P, Bernier SG, Liu G, Long K, Miyashiro J, Ranganath S, Jacobson S, Tang K, Im GJ,
Sheppeck J 2nd, Moore JD, Sykes K, Wakefield J, Sarno R, Banijamali AR, Profy AT, Milne GT, Currie MG, Masferrer JL.
Pharmacological characterization of IW-1973, a novel soluble guanylate cyclase stimulator with extensive tissue distribution,
antihypertensive, anti-inflammatory, and antifibrotic effects in preclinical models of disease. J Pharmacol Exp Ther 2018;365:664-75.
42. Stelzner TJ, O’Brien RF, Yanagisawa M, Sakurai T, Sato K, Webb S, Zamora M, McMurtry IF, Fisher JH. Increased lung endothelin-1
production in rats with idiopathic pulmonary hypertension. Am J Physiol 1992;262:L614-20.
43. Humbert M, Labrune P, Sitbon O, Le Gall C, Callebert J, Herve P, Samuel D, Machado R, Trembath R, Drouet L, Launay JM,
Simonneau G. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis. Eur Respir J 2002;20:59-
65.
44. Hood KY, Mair KM, Harvey AP, Montezano AC, Touyz RM, MacLean MR. Serotonin signaling through the 5-HT1B receptor and
NADPH oxidase 1 in pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2017;37:1361-70.
45. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of
thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5.
46. Mahajan CN, Afolayan AJ, Eis A, Teng RJ, Konduri GG. Altered prostanoid metabolism contributes to impaired angiogenesis in
persistent pulmonary hypertension in a fetal lamb model. Pediatr Res 2015;77:455-62.
47. Li H, Elton TS, Chen YF, Oparil S. Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol 1994;266:L553-60.
48. Weir EK, Hong Z, Varghese A. The serotonin transporter: a vehicle to elucidate pulmonary hypertension? Circ Res 2004;94:1152-4.
49. Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA. Cyclooxygenase-2 acts as an endogenous brake on endothelin-1 release by
human pulmonary artery smooth muscle cells: implications for pulmonary hypertension. Mol Pharmacol 2002;62:1147-53.
50. Chandra SM, Razavi H, Kim J, Agrawal R, Kundu RK, de Jesus Perez V, Zamanian RT, Quertermous T, Chun HJ. Disruption of the
apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 2011;31:814-20.
51. Yang P, Maguire JJ, Davenport AP. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular
system. Trends Pharmacol Sci 2015;36:560-7.
52. Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, Upton PD, Crosby A, Sawiak SJ, Carpenter TA, Glen RC, Morrell
NW, Maguire JJ, Davenport AP. Elabela/Toddler is an endogenous agonist of the apelin apj receptor in the adult cardiovascular system,
and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension.
Circulation 2017;135:1160-73.
53. Fediuk J, Gutsol A, Nolette N, Dakshinamurti S. Thromboxane-induced actin polymerization in hypoxic pulmonary artery is
independent of Rho. Am J Physiol Lung Cell Mol Physiol 2012;302:L13-26.
54. Hinton M, Gutsol A, Dakshinamurti S. Thromboxane hypersensitivity in hypoxic pulmonary artery myocytes: altered TP receptor
localization and kinetics. Am J Physiol Lung Cell Mol Physiol 2007;292:L654-63.
55. Sikarwar AS, Hinton M, Santhosh KT, Chelikani P, Dakshinamurti S. Palmitoylation of Galphaq determines its association with the
thromboxane receptor in hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol 2014;50:135-43.
56. Santhosh KT, Elkhateeb O, Nolette N, Outbih O, Halayko AJ, Dakshinamurti S. Milrinone attenuates thromboxane receptor-mediated
hyperresponsiveness in hypoxic pulmonary arterial myocytes. Br J Pharmacol 2011;163:1223-36.
57. Rondelet B, Van Beneden R, Kerbaul F, Motte S, Fesler P, McEntee K, Brimioulle S, Ketelslegers JM, Naeije R. Expression of the
serotonin 1b receptor in experimental pulmonary hypertension. Eur Respir J 2003;22:408-12.
58. Milara J, Gabarda E, Juan G, Ortiz JL, Guijarro R, Martorell M, Morcillo EJ, Cortijo J. Bosentan inhibits cigarette smoke-induced
endothelin receptor expression in pulmonary arteries. Eur Respir J 2012;39:927-38.
59. Falcetti E, Hall SM, Phillips PG, Patel J, Morrell NW, Haworth SG, Clapp LH. Smooth muscle proliferation and role of the prostacyclin
(IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:1161-70.
60. Kuwano K, Hashino A, Asaki T, Hamamoto T, Yamada T, Okubo K, Kuwabara K. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]
butoxy]-N-(methylsulfonyl)acetam ide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol
Exp Ther 2007;322:1181-8.
61. Schermuly RT, Pullamsetti SS, Breitenbach SC, Weissmann N, Ghofrani HA, Grimminger F, Nilius SM, Schror K, Kirchrath JM,
Seeger W, Rose F. Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respir Res 2007;8:4.
62. Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, Hess P, Iglarz M, Clozel M, Nayler O. Selexipag active
metabolite ACT-333679 displays strong anticontractile and antiremodeling effects but low beta-arrestin recruitment and desensitization